CHMP recommends EU approval for Roche ’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ ® (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals